Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)
Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice ("GLP") toxicology analysis of intravenously administered Rutherrin® has commenced.Rutherrin® is...